Phillip A. Sharp is an Institute Professor (highest academic rank) at the Massachusetts Institute of Technology. He is Advisory Board Chair of the Jameel Clinic as well as a member of the Department of Biology and the Koch Institute for Integrative Cancer Research. He was founding director of the McGovern Institute, a position he held from 2000 to 2004. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark work in 1977 provided the first indications of “discontinuous genes” in mammalian cells. The discovery fundamentally changed scientists’ understanding of gene structure and earned Sharp the 1993 Nobel Prize in Physiology or Medicine. Sharp has authored over 440 papers. He is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the Royal Society, UK. Among his many awards are the Gairdner Foundation International Award, the Lasker Basic Medical Research Award, and the National Medal of Science. His long list of service includes the presidency of the AAAS (2013) and Chair of the Scientific Advisory Committee of the SU2C Project, AACR. A native of Kentucky, Sharp earned a B.A. degree from Union College, Barbourville, KY, and a Ph.D. in chemistry from the University of Illinois, Urbana-Champaign. Sharp is a co-founder of Biogen and Alnylam Pharmaceuticals Inc.